Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area
Open Access
- 1 January 2017
- journal article
- research article
- Published by Medknow in Indian Journal Of Ophthalmology
- Vol. 65 (1) , 48-51
Abstract
Context (Background): Imiquimod (IMQ) 5% cream is an immunomodulatory and antitumorigenic agent, which was used as a topical treatment regimen, who had periocular basal cell carcinoma (BCC). Aim: This study aims to present three cases with large BCC at the medial canthal area treated with IMQ 5% cream. Materials and Methods: IMQ 5% cream was used in three patients with ages 45, 49, and 73 who preferred medical treatment over surgery. Following incisional biopsy IMQ cream was used once a day, 5 times a week and the patients were followed up weekly during 12 week treatment period and monthly after the clearance of the lesion. Results: Erythema and erosion on the surface of the lesion, injection of conjunctiva, burning and itching sensation, epiphora and punctate keratitis were seen in all patients during the treatment period. The ophthalmic side effects could be managed by topical lubricating eye drops and the inflammatory reactions resolved within 1 month after cessation of therapy. The patients were followed up for at least 3 years without tumor recurrence and the biopsies taken from the suspected area were found to be tumor free. Conclusion: Surgical excision of carcinoma of the eyelid at medial canthal area can be difficult without causing damage to the lacrimal system and reconstruction of the defect may need grafts or flaps. IMQ may provide an alternative therapy to surgery in certain cases.Keywords
This publication has 16 references indexed in Scilit:
- What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trialBMC Dermatology, 2012
- The ophthalmic side-effects of imiquimod therapy in the management of periocular skin lesionsBritish Journal of Ophthalmology, 2010
- Efficacy and Tolerability of Imiquimod 5% Cream to Treat Periocular Basal Cell CarcinomasJournal of Ocular Pharmacology and Therapeutics, 2010
- The SINS trial: A randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinomaTrials, 2010
- Imiquimod 5% Cream for the Treatment of Periocular Basal Cell CarcinomaOphthalmic Plastic & Reconstructive Surgery, 2010
- Imiquimod in the treatment of eyelid basal cell carcinomaActa Ophthalmologica Scandinavica, 2007
- Imiquimod in the treatment of eyelid basal cell carcinomaActa Ophthalmologica Scandinavica, 2007
- Topical therapy with imiquimod for eyelid lesionClinical & Experimental Ophthalmology, 2006
- Immunotherapy With Imiquimod 5% Cream for Eyelid Nodular Basal Cell CarcinomaAmerican Journal of Ophthalmology, 2005
- Interventions for basal cell carcinoma of the skin: systematic reviewBMJ, 2004